In this multicenter study, the authors retrospectively identified predictors of treatment success in syphilitic uveitis. Source: AAO
The cost to restore sight to the blind will be a “responsible” $425,000 per eye, Spark Therapeutics announced this week. The company set the price of Luxturna and laid out options for insurers and patients to deal with the financial burden. Source: AAO
This week, animal eye docs unbox a massive whale eye, a man mistakes superglue for eyedrops and Santen Pharmaceutical redoubles efforts to market a nonsteroidal drug for uveitis. Source: AAO
Investigators evaluated demographic and geographic patterns in the use of ranibizumab versus bevacizumab for newly diagnosed neovascular AMD among Medicare beneficiaries in the US. Source: AAO
Investigators explored the effect of spaceflight on the anatomical configuration of the brain and in cerebrospinal fluid spaces. Source: AAO
Canadian drugmaker Valeant Pharmaceuticals announced the approval of the first over-the-counter medication containing low-dose brimonidine tartrate (Lumify) for the treatment of eye redness. Source: AAO
The latest Ophthalmic Technology Assessment explores the most effective method for disinfecting reusable tonometers. Source: AAO
This Ophthalmic Technology Assessment by the Pediatric Ophthalmology/Strabismus Panel reviewed published literature regarding the efficacy of topical atropine for preventing myopic progression in children. Source: AAO
Patients with glaucoma can reliably perform self-tonometry using the portable rebound device, according to this prospective study. Source: AAO
A suite of formerly untreatable, progressively blinding retinal diseases may now be halted or even reversed, thanks to FDA approval of the gene therapy agent, Luxturna. The announcement marks the first U.S. approval of a gene therapy for an inherited disease. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »